These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 22695964)

  • 21. Expression of CCR5 and its ligands CCL3, -4, and -5 in the tear film and ocular surface of patients with dry eye disease.
    Choi W; Li Z; Oh HJ; Im SK; Lee SH; Park SH; You IC; Yoon KC
    Curr Eye Res; 2012 Jan; 37(1):12-7. PubMed ID: 22029739
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Upregulation of the IL-33/ST2 pathway in dry eye.
    Wang S; Zhang H
    Mol Vis; 2019; 25():583-592. PubMed ID: 31673224
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Tear osmolarity measurements in dry eye related to primary Sjögren's syndrome.
    Utine CA; Bıçakçıgil M; Yavuz S; Çiftçi F
    Curr Eye Res; 2011 Aug; 36(8):683-90. PubMed ID: 21780917
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immunomodulatory effect of the topical ophthalmic Janus kinase inhibitor tofacitinib (CP-690,550) in patients with dry eye disease.
    Huang JF; Yafawi R; Zhang M; McDowell M; Rittenhouse KD; Sace F; Liew SH; Cooper SR; Pickering EH
    Ophthalmology; 2012 Jul; 119(7):e43-50. PubMed ID: 22607938
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical utility of objective tests for dry eye disease: variability over time and implications for clinical trials and disease management.
    Sullivan BD; Crews LA; Sönmez B; de la Paz MF; Comert E; Charoenrook V; de Araujo AL; Pepose JS; Berg MS; Kosheleff VP; Lemp MA
    Cornea; 2012 Sep; 31(9):1000-8. PubMed ID: 22475641
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Analysis of the correlations of mucins, inflammatory markers, and clinical tests in dry eye.
    Zhang J; Yan X; Li H
    Cornea; 2013 Jul; 32(7):928-32. PubMed ID: 23538614
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Identification of tear fluid biomarkers in dry eye syndrome using iTRAQ quantitative proteomics.
    Zhou L; Beuerman RW; Chan CM; Zhao SZ; Li XR; Yang H; Tong L; Liu S; Stern ME; Tan D
    J Proteome Res; 2009 Nov; 8(11):4889-905. PubMed ID: 19705875
    [TBL] [Abstract][Full Text] [Related]  

  • 28. OCT assessment of tear meniscus after punctal occlusion in dry eye disease.
    Ibrahim OM; Dogru M; Kojima T; Matsumoto Y; Wakamatsu TH; Tsubota K; Fujishima H
    Optom Vis Sci; 2012 May; 89(5):E770-6. PubMed ID: 22466101
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Conjunctival cytokine expression in symptomatic moderate dry eye subjects.
    Narayanan S; Miller WL; McDermott AM
    Invest Ophthalmol Vis Sci; 2006 Jun; 47(6):2445-50. PubMed ID: 16723455
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Dysregulated Tear Fluid Nociception-Associated Factors, Corneal Dendritic Cell Density, and Vitamin D Levels in Evaporative Dry Eye.
    Khamar P; Nair AP; Shetty R; Vaidya T; Subramani M; Ponnalagu M; Dhamodaran K; D'souza S; Ghosh A; Pahuja N; Deshmukh R; Ahuja P; Sainani K; Nuijts RMMA; Das D; Ghosh A; Sethu S
    Invest Ophthalmol Vis Sci; 2019 Jun; 60(7):2532-2542. PubMed ID: 31195410
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Application of visante optical coherence tomography tear meniscus height measurement in the diagnosis of dry eye disease.
    Ibrahim OM; Dogru M; Takano Y; Satake Y; Wakamatsu TH; Fukagawa K; Tsubota K; Fujishima H
    Ophthalmology; 2010 Oct; 117(10):1923-9. PubMed ID: 20605216
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Alterations of tear neuromediators in dry eye disease.
    Lambiase A; Micera A; Sacchetti M; Cortes M; Mantelli F; Bonini S
    Arch Ophthalmol; 2011 Aug; 129(8):981-6. PubMed ID: 21825181
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Tear lipocalin and lysozyme concentrations in postmenopausal women.
    Srinivasan S; Joyce E; Boone A; Simpson T; Jones L; Senchyna M
    Ophthalmic Physiol Opt; 2010 May; 30(3):257-66. PubMed ID: 20444132
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Inflammatory markers in the tears of patients with ocular surface disease.
    Acera A; Rocha G; Vecino E; Lema I; Durán JA
    Ophthalmic Res; 2008 Oct; 40(6):315-21. PubMed ID: 18688174
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Analysis of inflammatory cytokines in the tears of dry eye patients.
    Massingale ML; Li X; Vallabhajosyula M; Chen D; Wei Y; Asbell PA
    Cornea; 2009 Oct; 28(9):1023-7. PubMed ID: 19724208
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of botulinum toxin type A on the treatment of dry eye disease and tear cytokines.
    Choi MG; Yeo JH; Kang JW; Chun YS; Lee JK; Kim JC
    Graefes Arch Clin Exp Ophthalmol; 2019 Feb; 257(2):331-338. PubMed ID: 30552510
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Correlation of interleukin-33 with Th cytokines and clinical severity of dry eye disease.
    Luo G; Xin Y; Qin D; Yan A; Zhou Z; Liu Z
    Indian J Ophthalmol; 2018 Jan; 66(1):39-43. PubMed ID: 29283120
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Tear film aberration dynamics and vision-related quality of life in patients with dry eye disease.
    Denoyer A; Rabut G; Baudouin C
    Ophthalmology; 2012 Sep; 119(9):1811-8. PubMed ID: 22591770
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Usefulness of double vital staining with 1% fluorescein and 1% lissamine green in patients with dry eye syndrome.
    Yoon KC; Im SK; Kim HG; You IC
    Cornea; 2011 Sep; 30(9):972-6. PubMed ID: 21705877
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Evaluation of Tear Protein Markers in Dry Eye Disease with Different Lymphotoxin-Alpha Expression Levels.
    Chen H; Chen H; Liang L; Zhong Y; Liang Y; Yu Y; Huang S; Lu X
    Am J Ophthalmol; 2020 Sep; 217():198-211. PubMed ID: 32209340
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.